This Article Full Text (PDF) Other Versions of this Article: IAI.01673-06v1 75/4/1794    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ekström, N. Search for Related Content PubMed PubMed Citation Articles by Ekström, N.

 Previous Article  |  Next Article 

Infect. Immun. doi:10.1128/IAI.01673-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Functional Antibodies Elicited by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial

National Public Health Institute (KTL), Helsinki, Finland

^* To whom correspondence should be addressed. Email: nina.ekstrom{at}ktl.fi.

	Abstract

In the Finnish Otitis Media Vaccine Trial the by now licensed pneumococcal conjugate vaccine containing polysaccharides conjugated to protein CRM₁₉₇ (PncCRM) and the experimental pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine (PncOMPC), showed similar efficacy profiles against acute otitis media, despite different antibody concentrations in sera. We now report the opsonophagocytic activities (OPA) in these sera. OPA, antibody concentration and avidity for serotypes 6B, 19F, and 23F were determined in sera of infants who received either pneumococcal conjugate (PCV) or control vaccine at 2, 4, and 6 months of age and either the homologous or pneumococcal polysaccharide vaccine at 12 months of age. OPA varied by vaccine and serotype. Majority of PCV recipients had positive OPA after the 4^th dose, while OPA was undetectable in the control group. Coinciding with the efficacy data, the concentration of antibodies required for 50% killing was low for 6B, and high for 19F for both PCVs. Contradictory to the efficacy data, PncOMPC induced lower functional capacity to 23F than PncCRM. OPA correlated with antibody concentration, while avidity and functional capacity of antibodies showed no correlation. The OPA data provides valuable additional information for serotype specific differences in protection and when evaluating serotype specific immunogenicity, and should thus be considered when defining serological correlates of protection.